
Financial Performance - Predictive Oncology reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for Q1 2024, compared to a net loss of $3.4 million in Q1 2023[1][14] - Revenue for Q1 2024 was $419,646, representing a 75% increase from $239,895 in the same period of 2023[8][14] - Gross profit margin improved to approximately 55% in Q1 2024, up from 50% in Q1 2023, primarily due to a change in sales mix[8][14] - Basic and diluted net loss per common share for Q1 2024 was $(1.04), compared to $(0.86) for Q1 2023[8][14] Cash and Liabilities - The company ended Q1 2024 with $5.2 million in cash, down from $8.7 million as of December 31, 2023[8][11] - Total liabilities increased to $6.5 million as of March 31, 2024, compared to $6.1 million as of December 31, 2023[8][11] Expenses - General and administrative expenses increased to $2.6 million in Q1 2024 from $2.3 million in Q1 2023, mainly due to higher professional fees[8][14] Collaborations and Research - Predictive Oncology is collaborating with Fujifilm to enhance drug safety by improving bacterial endotoxin testing, utilizing its EndoPrep™ technology[4] - The company is making progress on a $6.2 million Phase 2b grant for a novel intranasal flu vaccine in collaboration with FluGen[4] - An abstract from a study with UPMC Magee-Womens Hospital has been accepted for presentation at the ASCO 2024 Annual Meeting, focusing on machine learning models predicting survival outcomes in ovarian cancer patients[4]